Streetbeat News

KLTO

Klotho Neurosciences, Inc.

https://klothoneuro.com

Industry

Biotechnology

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Klotho Neurosciences, Inc. (NASDAQ: KLTO) has appointed Riad El-Dada, former US President of Merck, to its Board of Directors. This move is expected to strengthen Klotho's leadership in developing therapies for neurodegenerative and age-related disorders.

Portfolio Pulse from

December 03, 2024 | 4:15 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Molecular Templates (MTEM) saw a 96.6% increase, while Elevance Health (ELV) dropped by 12.47% following its Q3 earnings report. Other notable gainers include Klotho Neurosciences (KLTO) and Healthcare Triangle (HCTI), while Biodexa Pharmaceuticals (BDRX) and 180 Life Sciences (ATNF) were among the losers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 12:10 pm

TSMC shares surged 8.1% in pre-market trading due to better-than-expected Q3 results, with revenue up 39% YoY. Other stocks like Staffing 360 Solutions and Gevo also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 17, 2024 | 9:39 am

In Wednesday's after-market session, several health care stocks experienced significant price movements. Molecular Templates (MTEM) saw a remarkable increase of 189.2%, while HCW Biologics (HCWB) experienced a notable decline of 14.8%. Other gainers included Klotho Neurosciences (KLTO) and Chromocell Therapeutics (CHRO), while Biodexa Pharmaceuticals (BDRX) and Capricor Therapeutics (CAPR) were among the losers.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 8:31 pm

The article highlights significant intraday movements in healthcare stocks, with notable gainers including 180 Life Sciences, Korro Bio, and Universe Pharmaceuticals, and losers such as Novavax and Tevogen Bio Holdings.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

Klotho Neurosciences, Inc. (NASDAQ:KLTO) has appointed Peter Moriarty, co-founder of Shire Pharmaceuticals, as its new Chief Operating Officer. Moriarty's extensive experience in the pharmaceutical industry is expected to aid Klotho in advancing its pipeline of cell and gene therapies for aging and age-related diseases.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 10:03 am

In Thursday's after-market session, several health care stocks experienced significant price movements. Notable gainers included NewGenIvf Group (NIVF) with a 58.1% increase, and SunLink Health Systems (SSY) with a 17.13% rise. On the losing side, Klotho Neurosciences (KLTO) fell by 6.5%, and Humana (HUM) declined by 4.76%.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 8:31 pm

In Thursday's pre-market session, several healthcare stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, Tempest Therapeutics, and Portage Biotech, while Gritstone Bio and 10x Genomics were among the major losers.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 12:08 pm

BloomZ Inc. shares surged 64% in pre-market trading after being selected as the primary animation contractor for a new project. Other stocks also showed significant pre-market movements, including Tevogen Bio Holdings, CN Energy Group, and Wheeler Real Estate Investment Trust.

Portfolio Pulse from Avi Kapoor

October 10, 2024 | 9:54 am

Several healthcare stocks experienced significant intraday movements on Wednesday. Notable gainers included Inspire Veterinary, ModivCare, and I-MAB, while Eagle Pharmaceuticals and Windtree Therapeutics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.